ARTICLE | Clinical News
Biovail begins Phase III
February 4, 2000 8:00 AM UTC
BVF began a Phase III trial of its Buspirone once daily controlled release formulation to treat anxiety disorders. Buspirone is marketed in the U.S. by Bristol-Myers Squibb (BMY) in an immediate relea...